S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Literal federal measure citations: S. 832
2026 · 3rd Quarter (July 1 - Sep 30)
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Filed by DLA PIPER LLP (US).
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- DLA PIPER LLP (US)
- Filing UUID
- 91819ebe-be5f-4354-9ff1-4d12da7dd3bc
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Medicare policies.
Healthcare provisions in appropriations and budget legislation.
National security issues related to pharmaceutical industry, including supply chain.
Trade policies and agreements, including IP protections, and administrative tariff actions.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.